Salvage use of erlotinib in advanced non-small cell lung cancer with acquired resistance to gefitinib: Is a clinical benefit still achievable?

Chul Cho Byoung, Hang Kim Joo

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)678-680
Number of pages3
JournalAmerican Journal of Hematology/ Oncology
Volume6
Issue number12
Publication statusPublished - 2007 Dec 1

Fingerprint

Non-Small Cell Lung Carcinoma
Erlotinib Hydrochloride
gefitinib

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

@article{b041565c98f54ba892c3afadcaf498a2,
title = "Salvage use of erlotinib in advanced non-small cell lung cancer with acquired resistance to gefitinib: Is a clinical benefit still achievable?",
author = "Byoung, {Chul Cho} and Joo, {Hang Kim}",
year = "2007",
month = "12",
day = "1",
language = "English",
volume = "6",
pages = "678--680",
journal = "American Journal of Oncology Review",
issn = "1542-9520",
publisher = "U. S. Healthcare Communications LLC",
number = "12",

}

TY - JOUR

T1 - Salvage use of erlotinib in advanced non-small cell lung cancer with acquired resistance to gefitinib

T2 - Is a clinical benefit still achievable?

AU - Byoung, Chul Cho

AU - Joo, Hang Kim

PY - 2007/12/1

Y1 - 2007/12/1

UR - http://www.scopus.com/inward/record.url?scp=38349031024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349031024&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:38349031024

VL - 6

SP - 678

EP - 680

JO - American Journal of Oncology Review

JF - American Journal of Oncology Review

SN - 1542-9520

IS - 12

ER -